UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q/A
Amendment No. 1
(Mark One)
[X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the quarterly period ended March 31, 2019
or
[ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the transition period from _________to___________
Commission File Number: 000-51353
PROTAGENIC THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 06-1390025 | |
(State or other jurisdiction of | (I.R.S. Employer | |
incorporation or organization) | Identification No.) |
149 Fifth Avenue, Suite 500, New York, New York 10010
(Address of Principal Executive Office) (Zip Code)
(212) 994-8200
Registrant’s Telephone Number Including Area Code
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Ticker symbol(s) | Name of each exchange on which registered | ||
N/A | N/A | N/A |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes [X] No [ ]
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | [ ] | Accelerated filer | [ ] |
Non-accelerated filer | [X] | Smaller reporting company | [X] |
Emerging Growth Company | [ ] |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Indicate by check mark whether the registrant is a shell company (as defined in Rule 126-2 of the Exchange Act). [ ] Yes [X] No
As of May 15, 2019, there were 10,261,419 shares of common stock outstanding.
EXPLANATORY NOTE
The sole purpose of this Amendment No. 1 to the Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2019 of Protagenic Therapeutics, Inc. (the Company”) filed with the Securities and Exchange Commission on May 15, 2019 (the “Form 10-Q”) is to furnish Exhibits 101 to the Form 10-Q in accordance with Rule 405 of Regulation S-T.
No other changes have been made to the Form 10-Q. This Amendment No. 1 to the Form 10-Q speaks as of the original filing date of the Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the original Form 10-Q.
2 |
The following is a complete list of exhibits filed as part of this Form 10-Q/A. Exhibit numbers correspond to the numbers in the Exhibit Table of Item 601 of Regulation S-K.
Exhibit | Description | |
31.1 | Chief Executive Officer Certification as required under section 302 of the Sarbanes Oxley Act (€) | |
31.2 | Chief Financial Officer Certification as required under section 302 of the Sarbanes Oxley Act (€) | |
32.1 | Chief Executive Officer and Chief Financial Officer Certification pursuant to 18 U.S.C. section 1350 as adopted pursuant to section 906 of the Sarbanes Oxley Act * | |
101.INS | XBRL Instance Document (€) | |
101.CAL | XBRL Taxonomy Extension Schema Document (€) | |
101.SCH | XBRL Taxonomy Extension Calculation Linkbase Document (€) | |
101.LAB | XBRL Taxonomy Extension Label Linkbase Document (€) | |
101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document (€) | |
101.DEF | XBRL Taxonomy Extension Definition Linkbase Document (€) |
(€) | - Filed herewith. |
(*) | - Furnished, not filed, in accordance with item 601(32)(ii) of Regulation S-K. |
3 |
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: May 16, 2019 | Protagenic Therapeutics, Inc. | |
By: | /s/ Alexander K. Arrow | |
Chief Financial Officer |
4 |